Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy

Pilot Study to Investigate the Impact of Hypochlorite in the Prevention of Radiation Dermatitis

This pilot clinical trial studies Dakin's solution in preventing radiation dermatitis in patients with breast cancer undergoing radiation therapy. Radiation dermatitis is a skin condition in which the affected skin becomes painful, red, itchy, and blistered. Dakin's solution may help reduce dermatitis caused by radiation therapy.

PRIMARY OBJECTIVES:

I. To determine the percent change in women who experience grade 3 or 4 radiation dermatitis as defined by the Stanford Radiation Dermatitis Scoring System during radiation treatment for breast cancer compared to historical experience using standard skin care.

SECONDARY OBJECTIVES:

I. To assess the feasibility of daily application of the hypochlorite solution (Dakin's solution), and to assess levels of pain during radiotherapy treatment.

OUTLINE:

Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks.

After completion of study treatment, patients are followed up at 4-6 weeks.

Inclusion Criteria:

• Women with breast cancer who plan to undergo radiation therapy to the breast or chest wall
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Women with scleroderma or discoid lupus
• Women with inflammatory breast cancer as evidenced by clinical assessment
• Women with breast cancer involving the skin
• Women who have undergone prior radiotherapy to the chest wall and/or breast